Last updated: August 3, 2026
FIRVANQ KIT is an FDA-approved vancomycin hydrochloride powder for oral solution used primarily for Clostridioides difficile-associated diarrhea and enterocolitis caused by Staphylococcus aureus. The product is commercialized in the United States by ANI Pharmaceuticals. Its market is specialized rather than broad: demand depends on oral vancomycin treatment volume, pediatric and swallowing-related needs, hospital discharge prescribing, payer coverage, and competition from compounded solutions and generic vancomycin products.
ANI does not separately disclose FIRVANQ revenue, gross margin, prescription volume, or market share in its public financial statements. The product is reported within ANI's broader branded and generic pharmaceutical portfolio. A precise product-level financial trajectory therefore cannot be calculated from company filings alone. The available evidence supports a stable niche-product profile with limited volume potential, pricing sensitivity, and meaningful substitution risk.
What is FIRVANQ KIT and how is it used?
FIRVANQ KIT contains vancomycin hydrochloride powder that is reconstituted into an oral solution. It is available in multiple concentrations and package configurations, including kits designed to simplify pharmacy preparation and administration.
| Attribute |
FIRVANQ KIT |
| Active ingredient |
Vancomycin hydrochloride |
| Dosage form |
Powder for oral solution |
| Route |
Oral |
| U.S. regulatory application |
NDA 208029 |
| Primary indication |
C. difficile-associated diarrhea and enterocolitis |
| Commercial company |
ANI Pharmaceuticals |
| Initial FDA approval |
2016 |
| Therapeutic category |
Gastrointestinal anti-infective |
| Biosimilar exposure |
None |
| Primary substitutes |
Vancomycin capsules, compounded oral solution, fidaxomicin |
Oral vancomycin is not used to treat systemic infections because oral absorption is limited. Its principal commercial use is localized treatment of C. difficile infection in the gastrointestinal tract. The FDA-approved label specifies dosing by age, indication, and severity of infection. [1]
The kit format has practical value for pharmacies and patients. Reconstitution reduces the need for pharmacy-compounded oral vancomycin, while included measuring components and flavoring can support pediatric administration and outpatient use.
What is the FDA regulatory status of FIRVANQ?
FIRVANQ was approved by the FDA in 2016 under NDA 208029. The approval covers vancomycin hydrochloride for oral solution in specified concentrations and package sizes. The product is listed in FDA labeling and commercial drug databases as an approved prescription product. [1, 2]
The product is a small-molecule drug, not a biologic. Biosimilar competition is therefore irrelevant. The key regulatory competition comes from:
- Abbreviated New Drug Applications for equivalent oral vancomycin products.
- Vancomycin capsules.
- Pharmacy-compounded oral solutions.
- Fidaxomicin, which has a different mechanism and pricing profile.
- Hospital protocols that determine whether oral vancomycin or fidaxomicin is used.
The FDA label does not establish that FIRVANQ is clinically superior to vancomycin capsules. Its commercial differentiation is primarily formulation, convenience, approved labeling, and availability in a liquid dosage form.
What patents protect FIRVANQ KIT?
The core commercial protection for FIRVANQ is more likely to arise from formulation, package, regulatory, and brand-related rights than from broad composition-of-matter protection for vancomycin.
Vancomycin is an old antibiotic. The active pharmaceutical ingredient has no meaningful new-molecule exclusivity. Any relevant patent estate would therefore focus on formulation characteristics, reconstitution stability, flavoring, dosage concentration, container configuration, or manufacturing processes.
| Protection category |
Commercial relevance |
| Vancomycin composition patent |
Effectively unavailable for a legacy molecule |
| Oral-solution formulation patent |
Potentially relevant |
| Reconstitution and stability claims |
Potentially relevant |
| Kit and packaging claims |
Potentially relevant |
| Method-of-use claims |
Narrower relevance because treatment uses are established |
| Trademark rights |
Relevant to brand differentiation |
| FDA regulatory exclusivity |
Limited compared with new molecular entities |
The FDA Orange Book should be reviewed for current patent listings associated with NDA 208029 before making a launch or litigation decision. Public commercial materials do not establish a broad, long-duration patent moat comparable to a recently approved specialty drug. [3]
When does FIRVANQ lose exclusivity?
FIRVANQ's New Chemical Entity exclusivity is not the principal protection issue. Vancomycin predates the modern Hatch-Waxman exclusivity framework, and the product's value is tied to its FDA-approved oral-solution presentation rather than a new active ingredient.
The relevant loss-of-exclusivity questions are:
- Whether FDA has approved therapeutically equivalent generic oral-solution products.
- Whether those products are available commercially.
- Whether any Orange Book-listed formulation patents remain enforceable.
- Whether compounded products can satisfy demand at a lower cost.
- Whether payers require generic substitution or prior authorization for the branded product.
FIRVANQ can face competition even without a formal Paragraph IV litigation event. Pharmacy compounding and alternative vancomycin dosage forms can erode demand through substitution outside the traditional generic-launch pathway.
How many patents cover FIRVANQ KIT?
The number of commercially relevant patents cannot be inferred from the product label alone. Orange Book listings, patent-family records, and litigation filings must be reconciled because a single invention can generate multiple U.S. patent publications and continuations.
The practical patent assessment is more important than the raw patent count:
- A formulation patent may protect only a narrow combination of excipients or stability conditions.
- A process patent may be difficult to enforce against an imported or independently manufactured product.
- A package patent may not prevent a competitor from selling the same active ingredient in another container.
- A method-of-use patent may be vulnerable if the competing label uses a different indication or dosing statement.
- Expired vancomycin patents do not protect FIRVANQ's current commercial price.
For investment and launch analysis, the key document is the current FDA Orange Book entry for NDA 208029, supplemented by USPTO prosecution history and any Paragraph IV notice letters. [3, 4]
Which companies are challenging FIRVANQ?
Competition comes from three groups rather than a single direct challenger.
Generic drug manufacturers
Generic companies can target vancomycin oral solution through an ANDA if they can demonstrate pharmaceutical equivalence, bioequivalence where applicable, and compliance with applicable manufacturing requirements. The commercial impact depends on whether the generic is therapeutically equivalent and whether wholesalers and payers stock it.
Compounding pharmacies
Compounding pharmacies can produce oral vancomycin from powder or capsules under applicable federal and state rules. Compounded products may compete on price, concentration flexibility, and local availability. Their disadvantages include variable distribution, pharmacy workload, packaging differences, and less standardized commercial support.
Alternative branded therapies
Fidaxomicin, marketed in the United States as DIFICID, competes for the same broad infection-treatment budget. Guidelines may favor fidaxomicin in selected patients, but its acquisition cost is generally much higher than generic vancomycin. [5]
There is no biosimilar threat because FIRVANQ is not a biologic. The main risk is conventional generic and non-equivalent substitution.
What patent litigation affects FIRVANQ?
No major, widely reported patent-litigation event establishes a durable legal barrier around FIRVANQ in the public record used for this analysis. That does not eliminate Paragraph IV or formulation-litigation risk. It means the commercial case should not assume litigation-created exclusivity.
A prospective generic challenge would typically follow this sequence:
- ANDA filing referencing the listed drug.
- Paragraph IV certification if the applicant alleges that listed patents are invalid, unenforceable, or not infringed.
- Notice to the NDA holder and patent owner.
- Possible patent litigation within the statutory period.
- A potential 30-month stay of FDA approval, subject to statutory conditions.
- Launch after patent resolution, settlement, or expiration.
The absence of a public litigation event is commercially relevant. It suggests that market entry may be governed more by product economics and supply reliability than by a known settlement-controlled launch date.
What is the Orange Book status of FIRVANQ?
FIRVANQ is associated with NDA 208029. The Orange Book is the controlling source for:
- The reference-listed drug designation.
- Approved dosage forms and strengths.
- Therapeutic-equivalence ratings for approved generics.
- Listed patents and regulatory exclusivity.
- Patent-expiration and delisting information.
A branded oral solution can retain demand even after generic approval if the generic does not match the same concentration, package configuration, flavor profile, or pharmacy workflow. Conversely, a generic with a therapeutically equivalent rating and broad wholesaler distribution can cause rapid price erosion.
The Orange Book should be interpreted with DailyMed and FDA product-specific approval data because commercial availability is not always equivalent to regulatory approval. [2, 3]
How strong is the FIRVANQ patent estate?
The patent estate appears structurally weaker than the estate for a new chemical entity or a complex drug-delivery platform.
| Factor |
Assessment |
| Active ingredient protection |
Weak or absent |
| Formulation differentiation |
Moderate if claims are narrow and technically specific |
| Manufacturing barriers |
Moderate; liquid stability and quality control matter |
| Regulatory barrier |
Moderate for approved labeling and package configurations |
| Brand value |
Moderate in the oral-liquid niche |
| Generic substitution risk |
High |
| Biosimilar risk |
None |
| Litigation leverage |
Dependent on current Orange Book listings |
FIRVANQ's defensibility is strongest where the product solves practical problems that are difficult for a generic to reproduce at equal cost: stable reconstitution, acceptable taste, convenient packaging, and reliable distribution. Those attributes can support a premium but generally do not create a durable monopoly.
What is the financial trajectory for FIRVANQ?
ANI does not report FIRVANQ as a standalone revenue segment. Its filings aggregate revenue across branded pharmaceuticals, generic pharmaceuticals, and other product categories. As a result, product-level revenue, prescription counts, net price, and contribution margin are unavailable in public filings. [6]
The financial trajectory is best modeled through market drivers:
| Driver |
Expected effect |
| Continued C. difficile incidence |
Supports baseline demand |
| Pediatric and swallowing-related use |
Supports oral-solution demand |
| Generic oral-solution entry |
Reduces price and volume |
| Compounding availability |
Limits pricing power |
| Fidaxomicin adoption |
Creates branded treatment competition |
| Hospital discharge prescribing |
Supports outpatient prescriptions |
| Payer substitution rules |
Can accelerate generic conversion |
| Supply interruptions |
Can temporarily increase branded demand |
| Manufacturing costs |
Affect margin because the product has modest volume |
FIRVANQ is likely to have a mature-product financial profile: relatively predictable clinical demand, limited category growth, and sensitivity to generic competition. Revenue can remain stable if ANI maintains supply, reimbursement, and formulary access. A direct equivalent generic would likely create the largest downside event through lower net pricing and reduced prescription volume.
The product is unlikely to become a major growth driver for ANI unless the company expands distribution, obtains favorable contracting, acquires additional rights, or benefits from a sustained shortage of competing oral vancomycin products.
How does FIRVANQ compare with fidaxomicin and vancomycin capsules?
| Product |
Primary advantage |
Main commercial weakness |
Competitive position |
| FIRVANQ KIT |
FDA-approved oral liquid; useful for pediatric and swallowing-limited patients |
Higher cost than compounded or generic alternatives |
Niche branded product |
| Generic vancomycin capsules |
Low cost and broad availability |
Difficult for some patients to swallow; not a liquid |
Strong volume competitor |
| Compounded vancomycin solution |
Flexible concentration and potentially lower price |
Variable availability and pharmacy preparation burden |
Local or channel-specific competitor |
| Fidaxomicin |
Guideline-supported option with lower recurrence in selected settings |
High acquisition cost and payer restrictions |
Premium branded competitor |
Clinical guidelines increasingly distinguish patients by recurrence risk and treatment history. Fidaxomicin can benefit from guideline preference in selected cases, while vancomycin remains an important lower-cost therapy. [5]
What generic launch risks exist for FIRVANQ?
The highest-risk scenario is approval and commercial launch of a directly substitutable oral-solution generic. The effect would depend on the generic's therapeutic-equivalence rating, concentration, flavor, package size, and distribution.
Base case
ANI retains a niche share among prescriptions requiring an FDA-approved oral solution. Generic capsules and compounded solutions limit growth, but the product remains commercially viable.
Downside case
A therapeutically equivalent generic achieves broad wholesaler and payer placement. FIRVANQ experiences rapid price compression and declining volume.
Temporary upside case
A shortage, manufacturing disruption, or recall affects generic or compounded alternatives. FIRVANQ gains short-term volume and pricing leverage, but the benefit is unlikely to be permanent.
Structural downside case
Payers classify the product as a non-preferred branded alternative while pediatric and liquid-use demand remains too small to support premium pricing. Net revenue declines even without a formal generic launch.
What licensing deals support FIRVANQ?
FIRVANQ was developed by CutisPharma and is commercialized by ANI Pharmaceuticals. Public company filings do not separately identify FIRVANQ licensing income, royalty obligations, minimum purchase commitments, or product-level acquisition consideration. [6]
The commercial relationship should therefore be evaluated through ANI's reported product rights, intangible-asset disclosures, amortization schedules, and contingent-payment notes rather than through standalone FIRVANQ revenue data.
What geographic markets does FIRVANQ cover?
FIRVANQ is primarily a U.S. product. Its commercial value depends on U.S. FDA approval, U.S. wholesaler distribution, and U.S. reimbursement. International market coverage is not a major disclosed component of the product's public commercial profile.
Geographic expansion would require country-specific approvals, local product registration, manufacturing compliance, and reimbursement access. Those requirements reduce the likelihood that international sales will materially change the product's near-term trajectory.
Key Takeaways
- FIRVANQ KIT is an FDA-approved vancomycin oral solution marketed by ANI Pharmaceuticals.
- Its principal value is dosage-form convenience, not active-ingredient novelty.
- The product has no biosimilar risk because vancomycin is a small-molecule antibiotic.
- Generic oral solutions, vancomycin capsules, and compounded preparations are the primary competitive threats.
- Fidaxomicin competes for treatment decisions but occupies a higher-cost branded position.
- ANI does not disclose FIRVANQ-specific revenue, margin, prescription volume, or market share.
- Product-level growth is likely limited by the mature vancomycin market and substitution pressure.
- The decisive legal data are the current Orange Book listings, any Paragraph IV certifications, and the availability of therapeutically equivalent oral-solution generics.
- FIRVANQ's commercial durability depends on formulation execution, supply reliability, payer access, and the size of the liquid-dosage-form niche.
FAQs
Is FIRVANQ the same as vancomycin capsules?
No. Both contain vancomycin hydrochloride for oral treatment, but FIRVANQ is supplied as a powder that is reconstituted into an oral liquid. Capsules are a separate dosage form and may not be suitable for every patient.
Can pharmacies compound vancomycin oral solution instead of dispensing FIRVANQ?
Yes, pharmacies may compound oral vancomycin under applicable federal and state requirements. Compounded products can compete with FIRVANQ on price and concentration flexibility.
Is FIRVANQ approved for systemic bacterial infections?
No. Oral vancomycin has limited systemic absorption. FIRVANQ is labeled for intestinal infections, including C. difficile-associated diarrhea and enterocolitis.
Does FIRVANQ have orphan-drug exclusivity?
FIRVANQ's commercial protection is not based on orphan-drug exclusivity. Its market position comes from the FDA-approved oral-solution formulation and brand availability.
What event would most damage FIRVANQ revenue?
A broadly distributed therapeutically equivalent generic oral solution would pose the greatest direct risk. It could reduce both prescription volume and net pricing, particularly if payers impose automatic substitution or preferred-product requirements.
References
- U.S. Food and Drug Administration. (2016). FIRVANQ (vancomycin hydrochloride) powder, for solution: Prescribing information.
- National Library of Medicine. (n.d.). DailyMed: FIRVANQ- vancomycin hydrochloride powder, for solution.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Patent and Trademark Office. (n.d.). Patent Center.
- Infectious Diseases Society of America, & Society for Healthcare Epidemiology of America. (2021). Clinical practice guidelines for the management of Clostridioides difficile infection in adults: 2021 focused update. Clinical Infectious Diseases, 73(5), e1029-e1044.
- ANI Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
